Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEANUT study of pembrolizumab plus nab-paclitaxel in metastatic urothelial carcinoma after chemotherapy failure
2017-000579-10Phase 2Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and nab-paclitaxel in transitional cell carcinoma (TCC) and transitional cell carcinoma of the bladder (TCC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Progression-free survival. Started Dec 2020; status: completed.
02
Drugs
pembrolizumabnab-paclitaxel
03
Conditions
transitional cell carcinoma (TCC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on 2017-000579-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000579-10.